These findings suggest that reduction of EGFR-mediated glycolysis may be involved in the anti-tumor activity of EGFR TKIs, and thus monitoring [18F]-FDG-PET uptake has been used to predict therapeutic responses to EGFR TKIs in lung cancer patients [25–27]. The gene discussed is EGFR; the disease is neoplasm.